Exosomes

Introduction

Exosomes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Exosomes are small extracellular vesicles[@colombo2014] (EVs) ranging from 30 to 150 nm in diameter, released by virtually all cell types through the fusion of [@colombo2014]
multivesicular bodies (MVBs) with the plasma membrane. In the central nervous system, exosomes[@kalluri2020] are secreted by [neurons](/entities/neurons), [@raposo2013]
[astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia). [@emmanouilidou2010]

Biogenesis Pathway

Exosome formation begins with the inward budding of the limiting membrane of late endosomes, producing intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). Two principal pathways govern ILV formation: [@danzer2012]

ESCRT-Dependent Pathway. The Endosomal Sorting Complex Required for Transport (ESCRT) machinery consists of four complexes (ESCRT-0, -I, -II, -III) plus accessory proteins (ALIX, VPS4). ESCRT-0 recognizes ubiquitinated cargo on the endosomal membrane; ESCRT-I and -II induce membrane budding; and ESCRT-III mediates vesicle scission. ALIX bridges ESCRT-I and ESCRT-III and recruits specific cargo proteins. [@horie2024]

Introduction

Exosomes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Exosomes are small extracellular vesicles[@colombo2014] (EVs) ranging from 30 to 150 nm in diameter, released by virtually all cell types through the fusion of [@colombo2014]
multivesicular bodies (MVBs) with the plasma membrane. In the central nervous system, exosomes[@kalluri2020] are secreted by [neurons](/entities/neurons), [@raposo2013]
[astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia). [@emmanouilidou2010]

Biogenesis Pathway

Exosome formation begins with the inward budding of the limiting membrane of late endosomes, producing intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). Two principal pathways govern ILV formation: [@danzer2012]

ESCRT-Dependent Pathway. The Endosomal Sorting Complex Required for Transport (ESCRT) machinery consists of four complexes (ESCRT-0, -I, -II, -III) plus accessory proteins (ALIX, VPS4). ESCRT-0 recognizes ubiquitinated cargo on the endosomal membrane; ESCRT-I and -II induce membrane budding; and ESCRT-III mediates vesicle scission. ALIX bridges ESCRT-I and ESCRT-III and recruits specific cargo proteins. [@horie2024]

ESCRT-Independent Pathway. Ceramide-dependent budding occurs when neutral sphingomyelinase 2 (nSMase2) generates ceramide from sphingomyelin in the endosomal membrane. Ceramide's cone-shaped structure promotes spontaneous inward curvature. Tetraspanin-enriched microdomains (CD9, CD63, CD81) also facilitate ESCRT-independent ILV formation by clustering specific cargo. [@fiandaca2015]

Following ILV formation, MVBs either fuse with the plasma membrane (releasing ILVs as exosomes[@kalluri2020] into the extracellular space) or fuse with lysosomes for degradation. Rab GTPases (Rab27a, Rab27b, Rab11, Rab35) and SNARE proteins regulate the trafficking and membrane fusion events that determine exosome release ([Colombo et al., 2014](https://doi.org/10.1146/annurev-cellbio-101512-122326)). [@goetzl2016]

Molecular Composition

Exosomes carry a characteristic molecular cargo reflecting their endosomal origin: [@alvarezerviti2011]

| Component | Examples | Function | [@sun2025]
|---|---|---| [@bhatt2025]
| Tetraspanins | CD9, CD63, CD81 | Membrane organization; commonly used as exosome markers |
| [Heat shock proteins](/entities/heat-shock-proteins) | Hsp70, Hsp90 | Protein folding; antigen presentation |
| MVB biogenesis | ALIX, TSG101, VPS4 | ESCRT pathway components; exosome biogenesis markers |
| Membrane trafficking | Rab GTPases, annexins, flotillins | Vesicle transport and fusion |
| Nucleic acids | mRNA, miRNA, lncRNA, small RNA | Gene regulation in recipient cells |
| Lipids | Cholesterol, sphingomyelin, ceramide | Membrane rigidity; signaling |
| Disease-related cargo | [Aβ](/proteins/amyloid-beta-protein), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), [TDP-43](/proteins/tdp-43), PrP-Sc | Pathological protein spreading in neurodegeneration |

The lipid bilayer of exosomes[@kalluri2020] is enriched in cholesterol,
sphingomyelin, and glycosphingolipids relative to the parent cell membrane, conferring stability and resistance to degradation in biological fluids.
This composition enables exosomes[@kalluri2020] to survive transit
through blood, cerebrospinal fluid, and interstitial spaces ([Raposo & Stoorvogel, 2013](https://doi.org/10.1083/jcb.201211138)).

Brain-Derived Exosomes

Each CNS cell type releases exosomes[@kalluri2020] with distinct cargo profiles and functional roles:

Neuronal exosomes[@kalluri2020] carry synaptic proteins (AMPA/[NMDA receptor](/entities/nmda-receptor)] receptor subunits, synaptotagmin), neurotrophic factors (BDNF, GDNF), and -- critically in
disease -- misfolded tau] and [amyloid-beta](/proteins/amyloid-beta). Neuronal exosomes[@kalluri2020] express surface markers L1CAM (L1 cell adhesion molecule) and NCAM (neural
cell adhesion molecule), which are exploited for immunocapture-based isolation from blood.

Astrocytic exosomes[@kalluri2020] transport glutamate transporters, complement proteins, and in neurodegeneration, can carry [APP](/entities/app-protein) fragments and inflammatory mediators. They express GLAST and [GFAP](/entities/glial-fibrillary-acidic-protein) as surface markers.

Microglial exosomes[@kalluri2020] are enriched in inflammatory cytokines (IL-1-beta, TNF-alpha), complement components, and activated caspases. [microglia](/cell-types/microglia)

• Trans-synaptic release of exosomal [tau](/proteins/tau) follows neuroanatomical connectivity patterns consistent with Braak staging
• Depletion of exosomes[@kalluri2020] in animal models reduces [tau](/proteins/tau) spreading and downstream neurodegeneration

alpha-synuclein Transmission

In [Parkinson's Disease](/diseases/parkinsons-disease) and related synucleinopathies, [alpha-synuclein](/proteins/alpha-synuclein) oligomers and fibrils are packaged into exosomes[@kalluri2020] that function as "Trojan horses":

• Exosomes from PD patient CSF and brain contain aggregation-competent [alpha-synuclein](/proteins/alpha-synuclein) seeds
• Exosomal alpha-synuclein is taken up by neighboring [neurons](/entities/neurons) and glia, seeding de novo aggregation in the cytoplasm
• Misfolded alpha-synuclein strains with distinct conformations are propagated via exosomes[@kalluri2020], potentially explaining the clinical heterogeneity of synucleinopathies (PD vs. MSA vs. DLB)
• Blocking exosome release with nSMase2 inhibitors (e.g., GW4869) reduces alpha in animal models ([Emmanouilidou et al., 2010](https://doi.org/10.1523/JNEUROSCI.5699-09.2010); [Danzer et al., 2012](https://doi.org/10.1186/1750-1326-7-42))

TDP-43 Spreading in ALS and FTD

[TDP-43](/mechanisms/tdp-43-proteinopathy) Proteinopathy characterizes ~97% of ALS cases and ~45% of Frontotemporal Dementia (FTD) cases. Exosome-mediated TDP-43 propagation has been demonstrated through several lines of evidence:

• Exosomes derived from ALS-FTD cerebrospinal fluid are enriched in TDP-43 C-terminal fragments and induce TDP-43 aggregation in recipient cells
• TDP-43 secretion via extracellular vesicles[@colombo2014] is regulated by macroautophagy; impaired autophagosome-lysosome fusion (e.g., by bafilomycin A1 or granulin deficiency) promotes TDP-43 release in exosomes[@kalluri2020]
• A 2024 study in Nature Medicine demonstrated that plasma extracellular vesicle TDP-43 levels distinguish ALS and FTD-TDP from controls and from FTD-[tau](/proteins/tau), establishing EV TDP-43 as a potential diagnostic biomarker ([Horie et al., 2024](https://doi.org/10.1038/s41591-024-02937-4))

neuroinflammation

[Microglia exosomes[@kalluri2020] are potent amplifiers of neuroinflammation in neurodegeneration:

• Activated [microglia release exosomes[@kalluri2020] enriched in pro-inflammatory cytokines (IL-1-beta, IL-6, TNF-alpha), inflammasome components ([NLRP3](/mechanisms/nlrp3-inflammasome), ASC), and [reactive oxygen species](/entities/reactive-oxygen-species)
• These exosomes[@kalluri2020] propagate inflammatory signaling to distant brain regions, establishing a feed-forward loop of chronic neuroinflammation
• Microglial exosomes[@kalluri2020] also carry [amyloid-beta](/proteins/amyloid-beta) and tau seeds, linking inflammation to protein spreading
• A2-type reactive [astrocytes](/cell-types/astrocytes), induced by microglial exosomes[@kalluri2020], release neurotoxic exosomes[@kalluri2020] that damage neurons and oligodendrocytes
• Targeting microglial exosome release has emerged as a therapeutic strategy to break the neuroinflammation-neurodegeneration cycle ([Bhatt et al., 2025](https://doi.org/10.3389/fneur.2025.1708655))

Blood-Based Biomarker Potential

The ability to isolate brain-derived exosomes[@kalluri2020] from peripheral blood offers a minimally invasive window into CNS pathology:

| Biomarker Strategy | Marker | Application |
|---|---|---|
| Neuronal exosome isolation | L1CAM+, NCAM+ immunocapture | Enriches brain-derived EVs from plasma |
| Exosomal Abeta42/40 | Reduced ratio in AD | Correlates with [amyloid PET](/entities/amyloid-pet) positivity |
| Exosomal p-tau181/217 | Elevated in AD | Tracks tau pathology; may predict conversion from MCI to dementia |
| Exosomal alpha-synuclein | Elevated in PD/DLB | Distinguishes synucleinopathies from tauopathies |
| Exosomal TDP-43 | Elevated in ALS/FTD-TDP | Differentiates TDP-43 from tau pathology in FTD |
| Exosomal [NfL](/proteins/nfl-protein)) | Elevated across neurodegeneration | General neurodegeneration marker |
| Exosomal synaptosomal proteins | Synaptotagmin, neurogranin, GAP-43 | Tracks synaptic loss |

Neuronal-derived exosomes[@kalluri2020] (NDEs) isolated from plasma using L1CAM antibodies show AD-related changes in [amyloid-beta](/proteins/amyloid-beta), phospho-tau, and insulin signaling proteins up to 10 years before clinical diagnosis. However, the specificity of L1CAM as a neuronal exosome marker has been debated, and newer approaches using NCAM, synaptophysin, or multi-marker panels are under development ([Fiandaca et al., 2015](https://doi.org/10.1016/j.jalz.2014.07.003); [Goetzl et al., 2016](https://doi.org/10.1096/fj.201500799)).

Therapeutic Applications: Engineered Exosomes

Exosomes possess intrinsic properties that make them attractive drug delivery vehicles for the CNS:

[BBB](/entities/blood-brain-barrier) Penetration. Exosomes naturally cross the [blood-brain barrier](/entities/blood-brain-barrier) through multiple mechanisms including receptor-mediated transcytosis (via integrins, tetraspanins, and transferrin receptors), macropinocytosis by brain endothelial cells, and interactions between exosomal integrin alpha-v-beta-3 and vascular adhesion molecules. This natural BBB-crossing capability eliminates the need for the complex engineering required by synthetic nanoparticles ([Sun et al., 2025](https://doi.org/10.1002/mco2.70386)).

Engineering Strategies. Exosomes can be modified to enhance targeting and therapeutic payload:

• Surface decoration: Fusion of targeting peptides (RVG peptide for neuronal targeting, T7 peptide for transferrin receptor) to exosomal tetraspanins
• Cargo loading: Electroporation of siRNA, antisense oligonucleotides (ASOs), or small molecules into purified exosomes[@kalluri2020]; or genetic engineering of producer cells to package therapeutic mRNA/proteins
• Source selection: Mesenchymal stem cell (MSC)-derived exosomes[@kalluri2020] carry anti-inflammatory and neurotrophic factors; macrophage-derived exosomes[@kalluri2020] efficiently cross the BBB via integrin-mediated transcytosis

• ASO-loaded exosomes[@kalluri2020] targeting alpha-synuclein reduced expression and aggregation in PD mouse models, ameliorating dopaminergic neuron degeneration
• siRNA-loaded exosomes[@kalluri2020] targeting [BACE1](/proteins/bace1-protein)
• Curcumin-loaded exosomes[@kalluri2020] reduced neuroinflammation and amyloid burden in AD models
• MSC-derived exosomes[@kalluri2020] promoted neuronal survival and reduced infarct volume in stroke models

Current Research Frontiers (2024-2025)

Recent advances continue to expand the understanding and therapeutic potential of exosomes[@kalluri2020] in neurodegeneration:

• AI-guided engineering: Machine learning algorithms are being applied to predict optimal miRNA/drug encapsulation strategies and to design exosome surface modifications for enhanced CNS targeting
• Single-vesicle analysis: New technologies enable profiling of individual exosomes[@kalluri2020], revealing heterogeneity within EV populations that bulk analyses miss
• Liquid biopsy panels: Multi-analyte exosome panels combining [p-tau217](/biomarkers/p-tau-217), Abeta42, alpha-synuclein, and [NfL](/proteins/nfl-protein)) are being validated for differential diagnosis across the neurodegenerative disease spectrum
• Combination approaches: Exosomes co-loaded with anti-inflammatory miRNAs and protein-targeting ASOs aim to simultaneously address both spreading and neuroinflammation

Cross-Links

• [prion-like spreading](/mechanisms/prion-like-spreading)
• [tau protein]](/proteins/tau)
• [alpha-synuclein](/proteins/alpha-synuclein)
• [amyloid-beta](/proteins/amyloid-beta)
• [Microglia](/entities/microglia)
• [blood-brain barrier](/entities/blood-brain-barrier)
• [amyloid PET](/entities/amyloid-pet)
• [astrocytes](/cell-types/astrocytes)

Pathway & Interaction Diagram

Interactive diagram showing EXOSOMES key relationships in the SciDEX knowledge graph (15 connections shown).

External Links

• [International Society for Extracellular Vesicles (ISEV)](https://www.isev.org/)
• [ExoCarta — Exosome Database](http://www.exocarta.org/)
• [PubMed: Exosomes and Neurodegenerationhttps://pubmed.ncbi.nlm.nih.gov/?term=exosomes[@kalluri2020]+neurodegeneration)

See Also

• [Microglia](/entities/microglia)

Brain Atlas Resources

• Allen Human Brain Atlas: [Exosomes expression search](https://human.brain-map.org/microarray/search/show?search_term=Exosomes)
• Allen Mouse Brain Atlas: [Exosomes search](https://mouse.brain-map.org/search/index.html?query=Exosomes)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Exosomes developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Exosomes)

Background

The study of Exosomes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[DOI:10.1126/science.aau6977](https://doi.org/10.1126/science.aau6977)
[DOI:10.1146/annurev-cellbio-101512-122326](https://doi.org/10.1146/annurev-cellbio-101512-122326)
[DOI:10.1083/jcb.201211138](https://doi.org/10.1083/jcb.201211138)